What Happened?
Shares of medical device company LeMaitre Vascular (NASDAQ: LMAT) fell 12.2% in the afternoon session after the company reported weak first quarter 2025 results with a significant miss on full-year EPS guidance and underwhelming EPS guidance for next quarter. On the other hand, LeMaitre's full-year revenue guidance topped analysts' expectations and organic revenue outperform Wall Street's estimates. Still, this was a weaker quarter.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy LeMaitre? Access our full analysis report here, it’s free.
What The Market Is Telling Us
LeMaitre’s shares are not very volatile and have only had 9 moves greater than 5% over the last year. Moves this big are rare for LeMaitre and indicate this news significantly impacted the market’s perception of the business.
LeMaitre is down 13.5% since the beginning of the year, and at $79.16 per share, it is trading 26.7% below its 52-week high of $107.97 from November 2024. Investors who bought $1,000 worth of LeMaitre’s shares 5 years ago would now be looking at an investment worth $3,131.
Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
